Marlowe Share Discussion Threads

[wad collector] 06/11/2022 14:22

IC has this as a BUY this week, thinks the projected sales increase will happen.FWIW

I also note that last week Marlowe came number 3 in the week's biggest short increases, from 0.6 to 1.4%

[sogoesit] 17/9/2022 09:25

A LTH for me (B/even about 750) but maybe an accumulation opportunity.

[1nf3rn0] 14/9/2022 10:16

Another positive update today which should put a floor under the share price."Outlook and progress towards medium term targetsThe Group's run-rate revenues and adjusted EBITDA have grown to over GBP450m and GBP79m respectively. We remain confident of achieving our run-rate targets of GBP500m of revenues and GBP100m of adjusted EBITDA materially ahead of the end of FY24, as originally targeted, as we continue to build our positions across the highly attractive and resilient compliance markets that we occupy.The strong and increasing margins in our business, and its low capital intensity, makes our business highly cash generative and we continue to expect to generate at least 90% cash conversion per annum. This enables us to fund increasing organic investment in our business, as well as fund further bolt-on acquisitions."

[wad collector] 30/8/2022 21:03

God bless IC ; dropped to a 18 month low.

[wad collector] 01/7/2022 14:11

IC BUY tip today .

[1nf3rn0] 05/4/2022 12:27

Yes I dialled in too and was very impressed. The market seems to like it too as I see some chunky buys gone through since the event started. I wonder by how much they will exceed the 100m 2024 ebitda target. Maybe by 50%?

[adorling] 05/4/2022 10:37

Currently present at Capital Markets Day. impressive Management Team and even more impressive numbers across all financial metrics going forward. I am a buyer given “ahead of expectations” has been stated several times. Organic growth compounding M&A earnings enhancing acquisitions creating a strong defensive Company delivery accelerated growth.

[1nf3rn0] 31/3/2022 13:30

Back over 900p. Was nice to have the opportunity to add some cheap shares ahead of the capital markets day and investor Q&A on Tuesday 5th.

[1nf3rn0] 16/3/2022 08:30

Looking seriously undervalued now at 750p

[1nf3rn0] 25/1/2022 09:00

Last weeks' 1000p placing was well timed and now we PI's can buy at a near 10% discount!

[sogoesit] 20/1/2022 23:29

Looks like can avoid dilution hazard at not too high a cost.
May discount to sub-£10.
Looks interesting deal… just hope one day they stop acquiring and do some organic growing.

[dr biotech] 20/1/2022 15:07

Always difficult to know here whether the price drop is due to the deal or just the fundraising (or a bit of both). Seems sensible enough - if somewhat larger than normal than the typical size for MRL. They shrugged off the failed aquistion of renew, hopefully today just a temporary dip

Been a largely plain sailing ride for the last 8 or so months.

[1nf3rn0] 20/1/2022 07:47

A relatively large acquisition announced this morning which sounds like a very fair price and significantly earnings enhancive.Only gripe is not being able to participate in the fund raising as a PI.

[dr biotech] 22/12/2021 09:59

These have been a great run this year. I'm not so worried about the balance sheet yet, they seem to be able to buy companies and improved the margins - with the ocassional small raise when needed. The attempt to buy restore was a mistep, but other than than they seem to have everything in order. Long term hold for me.

[wad collector] 21/12/2021 23:02

Tipped in IC last week as a BUY at 930p, with fragmented competition and an acquisitive approach , but cautioning the rising balance sheet leverage.

[km18] 01/12/2021 16:41

Marlowe is a leading and highly innovative software services firm, providing risk and compliance advice, as well as testing and inspection expertise. As a result, the corporation is involved in the provision of risk assessments, and maintenance of security systems, with the purpose of optimising engineering services while mitigating software technical issues on behalf of clients. Consequently, a wide variety of stakeholders are interested in the firm’s ability to derive capital and re-invest cash into organic growth, yielding substantial returns for investors. This evidence is supported by the equity rally of £128.1m (£266.3m-£138.2m) with respect to last year. Additionally, the software service firm was able to effectively fund its operations, since the firm’s net cashflow soared from £9.4m to £58.8m. Today, Marlowe released its financial results, where adjusted profit before tax surged 127% to £15.2m, illustrating the effectiveness of the firm’s business model and corporate investment strategy.

[1nf3rn0] 01/12/2021 07:39

Commenting on the results Alex Dacre, Chief Executive, said:"We are pleased to report significant strategic, financial and operational progress in the period across the highly attractive compliance service and software markets that Marlowe serves.We have delivered on each of the four key strands of our strategy, deepening and broadening our presence across our markets via strong organic growth and completing twelve acquisitions during the first half, adding significant scale and additional compliance capabilities. We have further strengthened our operations by delivering effective integration programmes and organic investments whilst expanding our adjusted EBITDA margin by 300 bps. We have delivered major progress in our Digitalise strategy to become the market leader in compliance software with over 20% of our current profits now generated from software.Marlowe's business model continues to benefit from increasingly stringent regulations and increased ESG requirements on businesses. Much of what we do is non-discretionary, and over 85% of our revenues are recurring, as a result of the business-critical requirement for our services, and the regulation that underpins everything we do. Progress during and following the period underpins our confidence in materially overachieving against the financial targets we set in February 2021 to reach Group run-rate revenues of c.£500 million and adjusted EBITDA of c.£100 million by the end of FY2024.We have made a strong start to the second half, with good levels of organic growth, and as a result we announced last week that we expect to trade ahead of market expectations for the full year." Financial highlights · Strong first half performanceo  Group revenue up 61% to 134.5 million. Current annualised run-rate revenue of c. £335 milliono  Adjusted EBITDA of £21.8 million, up £10.3 million, and current annualised adjusted EBITDA of c.£60 milliono  Adjusted operating profit of £16.4 million, up £9.0 milliono  Adjusted profit before tax up 127% to £15.2 milliono  Adjusted EPS up 50% to 16.0po  Governance Risk and Compliance (GRC) division annualised adjusted EBITDA now accounts for over half of Group adjusted EBITDA

[dr biotech] 25/11/2021 18:36

Doubt there will be any dividends given the aggressive buying spree they are on. Looks a good long term hold though, nice to recover from the recent weakness

[wad collector] 25/11/2021 12:12

£10 looks on the near horizon. Hold and prosper I reckon.

[1nf3rn0] 25/11/2021 09:01

Big buys continuing to go through. Someone just took 257k shares at 925p.

Looks like a one way ticket over the next few years after yesterday's update.

[wad collector] 24/11/2021 13:36

That suggests an EPS of 129p , a P/E of 6.9! Though may not include the recent placing.
Time for some dividends?

[1nf3rn0] 24/11/2021 09:15

Great trading update today."The Group now expects to materially overachieve against FY 2024 target run rate revenue of c.GBP500 million and adjusted EBITDA(3) of c.GBP100 million"

[wad collector] 20/10/2021 12:37

Another acquisition, this time with a £50M placing @ 907p.

[wad collector] 04/10/2021 13:58

The determination to Acquire continues here..

Marlowe PLC Acquisitions of VinciWorks Legal & Hydro-X Group

[wad collector] 13/9/2021 14:34

But he is a pound up already, so perhaps it was newsworthy!